• U.S. hemp industry set for CAGR of 14 percent through 2022
• Interest in 23,000-acre ultra-high cannabidiol (CBD) hemp project in Kentucky
• Raises revenue guidance for 2019 to $70 million after announcing acquisition of hydroponics retailer

Despite the abstrusity that still surrounds the legal status of hemp, cultivation of the plant in the U.S. is undergoing a renaissance. During the Republic’s early years, citizens were legally obliged to grow the crop, and both Presidents Washington and Jefferson are reported to have done so. But legislative changes turned the thing on its head. Since hemp was a strain of cannabis sativa, as was marijuana, it became tainted with the same brush of illegality. Now, further changes in the legal framework are allowing the industry to emerge from its long winter, giving California-based Sugarmade, Inc. (OTCQB: SGMD) the opportunity to execute its ambitious plans to support cannabis cultivation. The company is one of the largest publicly traded hydroponics supply companies, with brands that include Zen Hydro, Carry Out Supplies, BudLife Cannabis Storage Solutions and Cali Grown Supplies.

Cultivation was perfectly legal in nineteenth century America. However, with the twentieth century a period of moral rectitude dawned, resulting in the Eighteenth Amendment that ushered in Prohibition in 1920 and the Marihuana Tax Act in 1937. The act effectively curtailed cultivation of hemp, but the final nail in the coffin came with the passage of the Controlled Substances Act (CSA) of 1970, which removed any substantive distinction between hemp and marijuana. Thereafter, for law enforcement agencies like the Drug Enforcement Administration (DEA), since both hemp and marijuana were strains of cannabis sativa, hemp was marijuana and marijuana was hemp.

Nevertheless, the legislative canopy keeps evolving. The Farm Bill of 2014 allowed states to set up pilot programs to investigate hemp and its commercial potential, making industrial hemp legal so long as its cultivation was in compliance with state regulations. In addition, case law confirmed that the Farm Bill would supersede the CSA in the event that there was conflict between the two. As a result, the DEA has bowed to the inevitable, removing CBD from Schedule 1. In September 2018, the agency issued an order placing “certain drug products that have been approved by the Food and Drug Administration (FDA) and which contain cannabidiol… derived from cannabis and no more than 0.1 percent tetrahydrocannabinols in schedule V.” This opens the way for further expansion of hemp cultivation. The total hemp market hit $820 million in 2017, according to the Hemp Business Journal, with hemp-derived CBD products accounting for $190 million of that. A CAGR of 14 percent is projected through 2022.

To serve this burgeoning market, Sugarmade has launched two divisions. ZenHydro is its online hydroponics store, which offers grow tents, lighting, nutrients and additives, instruments and tools and nearly everything else needed to grow cannabis. Then there’s BudLife Cannabis Storage Solutions, which offers a novel way to preserve the quality of cannabis flowers over long periods. Introduced in late December, the BudLife system has been able to preserve the integrity of cannabis flowers for up to six months.

Sugarmade is already a successful supplier of generic and custom printed products to the quick service sub-sector of the restaurant industry. Through its CarryOutSupplies subsidiary, the company provides the quick-serve restaurant sector with essential supplies such as cups, spoons and bottles. CarryOutSupplies allows smaller establishments to gain the marketing and advertising benefits of custom printed products without tying up large amounts of working capital.

Sugarmade recently announced a new corporate initiative in the hemp market. The company is to invest in Hempistry, Inc. a privately held Nevada corporation, which has begun planting an ultra-high cannabidiol (CBD) industrial hemp strain in Kentucky.  Additionally, Sugarmade expects to sign an agreement with Hempistry for hemp cultivation supplies. Hempistry has already begun planting and has signed an agreement reserving up to 23,000 acres of prime Kentucky farmland for its exclusive use for hemp cultivation.

Sugarmade is also in the process of acquiring Sky Unlimited, LLC, which, through its AthenaUnited.com operations and website, offers multiple popular hydroponic brands to several growing agricultural cultivation sectors. This planned acquisition has prompted Sugarmade to raise its revenue guidance for calendar 2019 from $30 million to $70 million.

For more information, visit the company’s website at www.Sugarmade.com

• BriaCell Therapeutics Corp. is working to develop the first off-the-shelf personalized immunotherapy for advanced breast cancer
• Clinical data reveals an excellent safety profile and potent anti-tumor activity for Bria-IMT in advanced breast cancer patients
• Combination study using Bria-IMT with Merck & Co., Inc.’s KEYTRUDA (pembrolizumab) in advanced breast cancer patients is ongoing
• Symposium covers the latest research on experimental biology, etiology, prevention, diagnosis and treatment of breast cancer and premalignant breast disease
• International audience from over 90 countries includes researchers, health professionals, physicians, oncologists and those with a special interest in breast cancer

An immuno-oncology focused biotechnology company, BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) will present details of its proprietary targeted immunotherapy technology in patients with advanced breast cancer during a poster session of the 2018 San Antonio Breast Cancer Symposium, scheduled for December 4-8 in San Antonio, Texas. Highlights of the company’s data on Bria-IMT as a monotherapy, demonstrating positive proof-of-concept and an initial assessment of safety and tolerability for Bria-IMT in combination with pembrolizumab (KEYTRUDA, manufactured by Merck & Co., Inc.) in advanced breast cancer patients, will be presented.

Presenting the poster will be Saveri Bhattacharya, DO, (http://ibn.fm/K2lpm) assistant professor of medical oncology at Thomas Jefferson University (http://ibn.fm/6UqCV), researcher at the NCI-designated Sidney Kimmel Cancer Center (http://ibn.fm/uapyF) at Jefferson Health (http://ibn.fm/MJJVW) and principal investigator (PI) of the study. BriaCell’s scientific team will be available to answer questions during the poster presentation.

Identified as poster no. 212 during the treatment immunotherapy (clinical) session and with the title “Initial safety and efficacy of a phase I/IIa trial of a modified whole tumor cell targeted immunotherapy in patients with advanced breast cancer,” BriaCell’s poster presentation is slated for Thursday, December 6, from 7:30 am to 9:00 am CT at the Henry B. Gonzalez Convention Center at 900 E. Market Street in San Antonio, Texas. The combination study is also listed on ClinicalTrials.gov with the National Institutes of Health as NCT03328026.

Improving the efficacy, safety and cost of care for those who are annually diagnosed with breast cancer continues to be at the forefront of medical research. An estimated 266,120 new cases of breast cancer are projected to be diagnosed in U.S. women during 2018, according to the National Cancer Institute (NCI) (http://ibn.fm/cUSKe). Female breast cancer represents 15.3 percent of all new cancer cases in the U.S., with nearly 41,000 women expected to die of the disease in 2018, according to the NCI. Breast cancer is identified as the most commonly occurring cancer in women around the globe and the second most common cancer overall, according to the World Cancer Research Fund International (http://ibn.fm/sVNYK).

”Early clinical findings of BriaCell’s novel, personalized immunotherapy treatment approach is generating great excitement,” Dr. Bill Williams, BriaCell’s president and CEO, noted in a news release.

“Bria-IMT has demonstrated positive proof-of-concept in advanced breast cancer, and we will delve into these data in San Antonio’s Breast Cancer conference which is a key oncology conference attended by leading scientists and oncologists worldwide. We have firm grounds to believe the anti-tumor effects of Bria-IMT can be greatly improved by combination with KEYTRUDA,” Williams continued (http://ibn.fm/O9cgn). “As we advance our technology and generate additional data, we will continue to discuss our novel therapeutic approach with potential partners to explore additional combinations. With the potential for a safe and effective treatment option for advanced breast cancer patients, we are committed to developing the shortest possible pathway to make these therapies available to these patients.”

Following the presentation at the symposium, copies of the abstract and poster will be available on www.BriaCell.com/Investor-Relations/Presentations

For more information, visit the company’s website at www.BriaCell.com

• SinglePoint’s cannabis market subsidiaries building direct-to-consumer supply chain for CBD products
• SingleSeed subsidiary introduced infused water and muscle salve products in October, with new sleep aid and a hair and beard oil expected promptly
• CBD is gaining traction as a medicinal product and wellness industry ingredient after Canada’s legalization drive and growing lawfulness in the United States

Technology innovator SinglePoint, Inc. (OTCQB: SING) is celebrating the rollout of new products to the cannabis-infused wellness market by subsidiary SingleSeed at the same time that its already-launched Lalpina CBD Water is reporting a successful first week of sales.

SingleSeed distributes hemp-based CBD (cannabidiol) products on a direct-to-consumer basis nationwide, and its website has only just begun offering its Cannasporin Muscle Salve and easy applicator Twist-Up Stick to soothe and heal damaged muscles as it reduces inflammation, while a CBD hair and beard oil and a new sleep aid tincture are expected in the coming weeks (http://ibn.fm/CEIKG).

Lalpina CBD Water comes in a 12-pack case and received 25 orders within the first week. Those transactions also helped drive the sales of other SingleSeed products, the company reported (http://ibn.fm/tICGo).

“We are thrilled at this first week of sales results, it has blown away our expectations especially when taking into consideration we have not yet added it to our mix of search marketing, most of the orders have been organic direct search for SingleSeed.com,” SinglePoint President Wil Ralston stated in the report.

SinglePoint specializes in acquiring small to mid-sized companies, emphasizing new technologies and providing investors opportunities to monetize assets ranging from payment processing and cannabis services to blockchain technologies and a cryptocurrency app co-created with AppSwarm (OTC: SWRM).

The new spate of SingleSeed’s CBD products are fulfilled directly by another SinglePoint subsidiary, Discount Indoor Garden Supply (“DIGS” or “DIGS Hydro”), which is able to provide bulk CBD from raw to “pure” isolate concentrated extract, as well as supplying white-labeled products.

In the wake of Canada’s nationwide legalization of all adult uses of cannabis in mid-October, SinglePoint is now exploring the ramifications of entering the Canadian market for a dual listing.

The company notes in its publications that Hemp Business Journal’s CBD market forecast anticipates growth to $2.1 billion by 2021, with $450 million of those sales coming from hemp-based sources (http://ibn.fm/LIvro). That provides a situation rife with opportunity to capitalize on e-commerce and physical outlets.

The CBD market is not only finding fertile ground in Canada’s legalization drive, but across the United States, where more than half of the states have established some type of authority for CBD use in medicinal applications. Because CBD’s chemically active properties do not produce the drugged euphoria of marijuana sibling tetrahydrocannabinol (THC) and because its users affirm that it provides relief from some chronic conditions, it is also gaining ground legislatively on the federal level. Congress is working toward a bipartisan approval of the 2018 Farm Bill, which would allow CBD-rich hemp to be grown as an agricultural commodity instead of a proscribed drug (http://ibn.fm/xj2h0), and the U.S. Food and Drug Administration recently approved a cannabis-based anti-seizure medication for pharmaceutical distribution, which drove the U.S. Drug Enforcement Administration to reclassify CBD as medicinal and legal in FDA-approved uses for the first time (http://ibn.fm/DGU9r).

For more information, visit the company’s website at www.SinglePoint.com

• Delivers effective, non-invasive, pain free skin care through its proprietary thermal therapy device technology
• Products approved by FDA and Health Canada as Class II medical devices
• Current product InterceptCS™ treats cold sores by application of controlled topical heat with no risk of burning the skin
• Current product TherOZap™ relieves pain, itch and inflammation of more than 20,000 types of insect and marine life bites and stings
• Future product now in R&D will incorporate thermal therapy device with medical cannabis or CBD gel, cream or salve
• Completed full IP review of patents, trademarks, and regulatory approvals for thermal therapy technology
• Global cosmeceuticals market projected to be worth more than $80 billion by 2023

Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF) is a medical device technology provider focused on addressing dermatological needs in the multi-billion-dollar cosmeceutical industry. The company’s effective, non-invasive and pain-free skin care is based on proprietary technology which has received Class II medical device status from the U.S. Food and Drug Administration.

Therma Bright’s portfolio includes products, devices and treatments that have both cosmetic and medicinal or therapeutic benefits, such as for relief of pain, itch and inflammation resulting from more than 20,000 types of insect and marine life bites and stings, including bees, wasps, hornets, mosquitos, black flies and jellyfish.

The Company’s current focus is to market its products online through various social media networks, and to eventually re-establish relationships with major North American and Global retailers.

Products

The company currently has two products on the market and another in the research and development phase:

InterceptCS™ is a thermal therapy device for the treatment and prevention of cold sores caused by the herpes simplex Type 1 virus*. Symptoms typically include sores around the mouth and lips which InterceptCS™ treats by application of controlled topical heat with no risk of burning the skin. When used at the first sign of an oncoming cold sore application of InterceptCS™ can prevent symptoms from developing. Infrared energy and light from the device penetrate the skin killing cells infected with the virus.

InterceptCS™ is available without prescription and comprises a battery powered ergonomic hand-held unit and a disposable single-use treatment activator. Therma Bright has completed prototyping of multi-use activators for InterceptCS™. The company plans to bring to market 5, 10 or 20 multi-use activations at prices that will offer customers greater value than the current single-use activator.

The other Therma Bright product currently under development is TherOZap™, a next generation thermal therapy device powered by the company’s core technology, which is approved by the FDA as a Class II medical device for the relief of the symptoms of insect bites. Therma Bright is testing a new easier-to-use prototype of the device for effectiveness against Zika virus and other diseases carried by mosquitos. Once the technology proves effective, Therma Bright intends to seek regulatory approvals and extend the prototype enhancements to a new commercial version of TherOZap™.

Cannabis

Therma Bright is also conducting research and development on a unique thermal therapy device that would incorporate medical grade cannabis or cannabidiol (“CDB”) sourced from hemp as a cream or gel to provide relief of back, knee and other joint pain. In preparation, the company has incorporated a wholly owned subsidiary to hold any technology for use or application of cannabis. Once approvals are secured, the company plans to sell the device through licensed cannabis producers or retailers across Canada and in international markets where use of cannabis has been legalized. The company has initiated trademark and patent protection for its thermal therapy technology incorporating medical cannabis. Therma Bright has indicated it will seek an acquisition to help further development of this product.

Market Opportunity

A report by market intelligence firm Mordor Intelligence put the global cosmeceuticals market at a value of nearly US$47 billion in 2017 and projects it to be worth more than $80 billion by 2023, growing at a rate of almost 9.5 percent annually. Medical research estimates that somewhere between 20 percent and 40 percent of the population suffer occasional cold sore outbreaks. In Canada those figures would mean five to 10 million people, and in the U.S. some 40 million to 80 million, with recurring cold sores, representing a substantial potential market for Therma Bright.

Management

Rob Fia serves as Therma Bright chairman and CEO. Fia has extensive contacts in the investment community and the financial sector as well as knowledge of various Canadian stock exchange listing processes and requirements. His 18 years in the investment business has included equity research and advising promising early stage companies on corporate finance. Therma Bright CFO Victor Hugo is a senior financial analyst at Marrelli Support Services Inc., for which he provides CFO, accounting, regulatory compliance, and management advisory services to companies listed on the TSX, TSX Venture Exchange and other Canadian and US exchanges.

**Based on double blind placebo study, the InterceptCS™ is approved by Health Canada for the claim “For prevention of cold sores when used within 3 hours of the onset of the prodrome.” The InterceptCS™ is not approved by the United States FDA or any claim of clinical indication, clinical efficacy, and/or cure or prevention of disease.

For more information, visit the company’s website at www.ThermaBright.com

• High growth telecommunication infrastructure and enterprise solution markets
• Technology explosion requiring company’s services
• Proven track record to sell and support Fortune 1,000 accounts, Tier 1,2,3 carriers
• Replicable, scalable services model with industry leading strategic partnerships
• Consistent revenue growth in AW Solutions and ADEX subsidiaries
• 100+ Master Service Agreements (MSA) in place
• Active acquisition strategy
• Trading at less than 8% trailing 12-month sales
• Proven management team with decades of executive leadership experience

Spectrum Global Solutions, Inc. (OTC: SGSI) is a leading single-source provider of end-to-end, next-generation wireless and wireline network infrastructure services and staffing solutions to the service provider (carrier) and corporate enterprise markets across the United States, Canada, Puerto Rico, Guam and the Caribbean. Spectrum Global Solutions provides services directly to carriers, aggregators, utilities, enterprise, Project Management Organizations (PMO) and Original Equipment Manufacturers (OEM) clientele through the following subsidiaries:

• AW Solutions, Inc. and AW Solutions Puerto Rico, LLC – Provides best-in-class communications infrastructure deployment services to carriers, OEMs, PMOs, utilities and enterprise clients by offering discrete and full turnkey service solutions for wireless and wireline clientele. AW Solutions holds professional engineering licenses in all contiguous states and in the District of Columbia and Hawaii; the Canadian provinces of British Columbia, Quebec, Ontario, Alberta and Newfoundland and Labrador; in Puerto Rico, Guam and the U.S. Virgin Islands.
• ADEX Corporation and ADEX Puerto Rico, LLC – An international service organization providing turnkey services and staffing solutions to telecommunications carriers and enterprise clients. Since 1993, ADEX has been assisting telecommunications companies throughout the project life cycle of any network deployment. ADEX and its service capabilities extend from the most basic installation functions to the most advanced engineering disciplines for today and tomorrow’s communications networks. Headquartered in Atlanta, Georgia, ADEX employs technical professionals and provides infrastructure services worldwide via domestic and international locations.
• Tropical Communications, Inc. – A state licensed electrical and underground utility contractor headquartered in Miami, Florida, providing all types of communications and infrastructure facility structured wiring services and solutions since 1984.

Through its subsidiaries, Spectrum Global Solutions is a comprehensive single-source provider for professional services and solutions for the development, deployment and maintenance of wireless/Distributed Antenna System (DAS)/small cell/wireline and fiber networks and infrastructure. The company’s services range in scope from a single activity to multiyear, multi-region, large-scale turnkey development contracts with a deepening pool of international, national, regional and local projects. Spectrum Global Solutions has completed more than 150,000 project activities on wireless, DAS, wireline and fiber networks across the United States utilizing licensed professional engineers, project managers, technicians and general contractors.

Market Opportunity

Growth projections for the telecom industry show a high growth cycle 2018 through 2025 with a four-fold increase in domestic mobile data traffic and up to $150 billion in fiber investment over the next 5-7 years (Deloitte, 2017). The worldwide explosion of smart phones, tablets and BYOD by customers demanding rapid deployment of new apps, private networks with better coverage and enhanced capacity provides a compelling enterprise opportunity market. The imminent rollout of 5G next generation networks, IOT (Internet-Of-Things) technology deployments, the FirstNet national public safety system, small cell/network densification, Dish Network Deployment, fiber and infrastructure network builds for backhaul and expanded deployments, new FCC spectrum auctions and upgrades to 4G, DAS and small cell networks are contributing to a projected $157 billion in U.S. telecommunication carrier capital expenditures by 2021.

Management

CEO Roger Ponder has served as a director of Spectrum Global Solutions since April 2017. Ponder served as President/CEO of Summit Capital Advisors, LLC, and Summit Broadband, LLC a provider of consulting services to private equity and institutional banking entities in the telecommunications, cable and media/internet sectors. He also served as a member of the board of directors of InterCloud Systems, Inc. and served as its Chief Operating Officer from November 2012 to March 2015. Prior to that Ponder retired from Time Warner Kansas City Division as President/CEO. Ponder brings extensive business development, strategic planning and operational experience to the Company.

Keith Hayter is President of Spectrum Global Solutions and has served as a director of the Company since April 2017. Hayter has also served as the Chief Executive Officer and President of AW Solutions Inc. and AW Solutions Puerto Rico LLC since November 2006. He was Vice President and General Manager of Alcoa Wireless Services from 2001-2006. Hayter served in both the U.S. and British armies and brings extensive multi-national experience in the start-up, development, management and growth of companies in the telecommunication, engineering and construction industry.

For more information, visit the company’s website at www.SpectrumGlobalSolutions.com

• The Supreme Cannabis Company saw record year-over-year growth with its most recent quarterly report
• Company’s reach includes six provinces, including prized Ontario, and international market for medical cannabis oil
• Supreme Cannabis’s efforts to ride industry’s rising tide include acquisition of strategic communications firm to boost its brand

The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF) (FRA: 53S1) is preparing a December 10 report to shareholders on the company’s strategic plan for 2019 to build on a year of record revenues and the prospects that an emerging legal industry presents in Canada.

The Supreme Cannabis Company reported in its recent quarterly update that its sales grew by 229 percent year-over-year from $1.56 million to $5.14 million (http://ibn.fm/cGWYF). With Canada’s nationwide legalization of full-range use of cannabis in October and legal retail outlets’ challenges in overcoming supply shortages (http://ibn.fm/nN9Yo), Supreme Cannabis is riding a rising tide in which cannabis cultivators are rushing to meet exceptional market demand.

Supreme Cannabis is well positioned to score in the game despite its junior cap profile. In terms of production capacity, the company’s 342,000-square-foot 7ACRES facility includes room to grow from its initial 30,000-square-foot flowering rooms. While Supreme Cannabis currently grows about 13,330 kilograms of cannabis per year, the company expects to boost its production to 50,000 kilograms of capacity by the end of the year.

The company has also achieved success in lining up distribution channels in the adult-use recreational cannabis market, selling directly to consumers in six Canadian provinces, including Ontario. Its agreement to supply market leader Tilray with product for medical cannabis patients in Canada gives 7ACRES a big-league connection, and the company’s international potential is forming around a recent partnership agreement and 10 percent ownership stake in Medigrow, based in Lesotho, to distribute medical cannabis oil for the international market (http://ibn.fm/pVIQ9).

As part of its expansion and marketing effort following nationwide legalization, Supreme Cannabis reached an agreement to acquire communications firm Bayfield Strategy, Inc., which is expected to help Supreme Cannabis shore up its brand to appeal to the premium quality market (http://ibn.fm/j0q7s).

“We believe that by respecting the plant, the people who care for it and the people who ultimately consume it, we have built a culture of continual improvement where consumers can expect that each flower experience is better than the last,” Supreme Cannabis President John Fowler stated in a recent news release (http://ibn.fm/iTpzz).

“7ACRES flower is focused on pleasing three primary senses: aroma, visual appeal and flavour. Through an intensive phenotype selection-process, we selected our four core strains to maximize the objective and subjective quality across these three categories,” he added.

The North American cannabis market alone was recently projected to hit $41 billion this year by researchers at Amadee & Company, Inc. before an anticipated climb to $95 billion in 2026 (http://ibn.fm/IsvIT), but the ascendance of the cannabis industry should be no surprise, given the outsized attention from the media to cannabis’s wide array of possible uses and its popularity with consumers as legal availability has expanded.

For more information, visit the company’s website at www.Supreme.ca

• LXRP partners with Cultivating Wellness Inc. (“CW”) to formulate the ChrgD+ premium brand and will now focus on selling it to CW’s national distribution network of retailers
• The two-gram powder packets are water soluble and can be added to any hot/cold beverage; they are a ready-mix hemp oil supplement that can be added to drinks, such as coffee
• DehydraTECH has already received multiple patents, and LXRP is a drug delivery platform innovator; the introduction is seen as a first step in the relationship between the companies

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) introduction of ChrgD+ powder packets, which can add multi-spectrum hemp oil to any hot or cold drink, leverages the trademarked ability of the company’s DehydraTECH to deliver cannabinoids. LXRP’s partnership with Cultivating Wellness Inc. (“CW”), which formulated the product, is seen as an important combined effort (http://ibn.fm/HALyy).

LXRP has not only partnered with CW as the manufacturer of ChrgD+; it also serves as the distributor of the product to its national network of customers, such as convenience stores, specialty retailers, national accounts and grocery chains. It is seen as the beginning of an important partnership between the two companies.

In a news release, Chris Bunka, CEO of LXRP, said, “It’s a simple way to add a multi spectrum powdered hemp supplement to your favorite beverage at any time and enjoy its fast-acting, non-altered taste with no oily residue. Lexaria’s ChrgD+ product format is being evaluated by others for use in their psychoactive cannabinoids products sector as per our proven track record as a technology provider to the industry.”

Based in British Columbia, Canada, LXRP is a biotechnology company and drug delivery platform innovator that has developed DehydraTECH technology, which has shown faster and more effective delivery of cannabinoids and nicotine. LXRP’s IP portfolio already includes a patent for oral delivery of all cannabinoids. The newest patents are to protect LXRP’s cannabinoid-infused beverage compositions. The compositions use both non-psychoactive cannabinoids, such as CBD, and also psychoactive cannabinoids, such as THC.

LXRP has a growing IP portfolio and will license in any of the countries worldwide where its technology already has a patent or is patent-pending. DehydraTECH is its proprietary absorption technology platform. It hopes to be granted two new Australian patents by year’s end. If patents applied for are issued, LXRP will then hold 12 issued patents within its first patent family, “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof.” It recently received two new U.S. patents related to cannabinoid-infused beverage compositions using DehydraTECH.

For more information, visit the company’s website at www.LexariaBioscience.com

• Working to reduce the world’s dependence on pharmaceuticals with natural remedies
• Providing multiple product lines meeting the consumer’s desire for natural, organic ingredients
• Uniquely positioned to service two markets that are expected to see substantial growth

Phivida Holdings Inc. (CSE: VIDA) (OTCQX: PHVAF), a hemp-cultivated cannabinoid innovator, believes that the best approach to maintaining health is to use ancient Eastern traditions of whole plant medicine with modern Western principles of naturopathic science. The company has developed products that promote a busy, active lifestyle through the use of natural plant-based ingredients that fuel and energize the body. A large part of Phivida’s mission is to provide food, beverage and clinical product choices that help reduce the world’s dependence on pharmaceuticals.

Consumers are shifting away from pharmaceutical companies and looking for natural remedies. Phivida is supplying this growing shift with two product lines, Vida+ and Oki. Vida+ (www.HempVidaPlus.com) offers a line of clinical hemp oil extracts and capsules. Oki (www.FeelOki.com) is a new line of consumer beverages and health supplements infused with active hemp extract. Oki beverages come in iced teas and flavor-infused water, with four different flavors of each. There is also a line of Oki tinctures and capsules. All of Phivida’s products use non-GMO, natural ingredients; are plant-based; and are vegan-friendly, and of its drinks are packaged in 100 percent recyclable glass.

In addition to products, Phivida is working to educate the consumer through its online Knowledge Center (http://ibn.fm/UM05x). As CBD increases in popularity, the myth around it grows as well. The Knowledge Center is a place where consumers can receive “clear, simple, science-based information” surrounding CBD. The site sets out to answer questions such as why people may choose hemp, what is CBD, what effect CBD can have on one’s body, how to properly integrate it into one’s health routine and more.

The company is uniquely positioned within an industry that’s ready to explode. With laws surrounding CBD changing and a beverage market that’s estimated to reach approximately $14 billion by 2020, the Oki product line is sitting in a unique market niche. Add to this that the hemp extract market is predicted to hit $22 billion by 2022 (http://ibn.fm/VhmfE), and Phivida becomes a company that’s worthy of close attention.

For more information, visit the company’s website at www.Phivida.com

• Partnering with Dermagate to improve the health of women worldwide
• Working toward qualification of an accreditation that will open more doors worldwide
• A promising year lays ahead with access to additional medical devices for ETST and an accelerated-to-market certification process for Hygee

Earth Science Tech, Inc. (OTCQB: ETST), a biotech company developing and marketing health-oriented products, has partnered with Dermagate, a fast growing company specializing in the manufacturing of dermatology and wound care products, to manufacture Hygee medical devices. A recent press release (http://ibn.fm/wDFw5) emphasizes that both companies share a concern for the health of women worldwide, making them a natural fit in the production and distribution of this self-sampling kit that allows women to test for sexually transmitted infections (STIs) in the privacy of their own homes.

Hygee has already been proven successful in detecting chlamydia. Testing for additional STIs and non-STI infections will be added soon. The goal of the current medical device is to help reduce the overall spread of chlamydia and help women avoid the dangerous complications of this STI. By providing an affordable, discreet testing procedure, ETST is empowering woman to take charge of their health. Dermagate is making it possible to produce and distribute these kits worldwide.

Dermagate holds the necessary ISO 13485:2013 certifications that will allow for distribution and has already begun the application process for the new Medical Device Single Audit Program (MDSAP) certification of all of its products, including Hygee. The MDSAP will soon replace the ISO 13485:2013 certification. Australia, Brazil, Canada, Japan and the United States are five major markets that will soon adopt the new certification. The advantage of MDSAP, which is also being considered by additional countries, is that one accreditation covers all participating countries rather than having to earn a new accreditation for every individual country.

Next year promises to be a productive one for ETST, as this new partnership will give the company access to additional medical devices for distribution. Certification for the distribution of Hygee in Canada is expected to take place in January. Certification for distribution in various other countries is anticipated in mid-2019. In addition to Hygee, two new nutraceutical products are scheduled to be launched in the coming year.

“The volume of first-year sales for Hygee will probably be far more than anticipated,” Gaétan Houle, president and CEO of PharmaGate Group Inc. and Dermagate, stated in a news release. “We are not afraid of success. We are able to scale the production to any level needed to meet the worldwide market needs.”

For more information, visit the company’s website at www.EarthScienceTech.com

• Medical Cannabis Payment Solutions serves the legal cannabis industry with a first-class, end-to end payment processing system
• Its payment architecture is called “Go”
• The company’s is committed to helping businesses process payments securely

Medical Cannabis Payment Solutions (OTC: REFG) provides payment and management solutions to the legal cannabis industry. The company serves this industry with a premier end-to end payment processing system. This proprietary payment system is called “Go.” A FinCEN (Financial Crimes Enforcement Network) compliant enterprise, Medical Cannabis Payment Solutions has its corporate office in Cheyenne, Wyoming.

Marijuana Business Daily noted in a June 2018 article that the industry is suffering banking woes and searching for solutions to this issue (http://ibn.fm/qFUYm). This is where Medical Cannabis Payment Solutions comes in, as it is a first-tier merchant processing cannabis industry pioneer. Fundamentally, its state-of-the-art system tracks sales and tax collection and does away with the need to deal in cash-only transactions. The company’s “Go” platform and technology is expressly targeted to the cannabis industry.

Medical Cannabis Payment Solutions permits merchant clients to sign up online on its site. Furthermore, the company provides bank accounts online. Therefore, cannabis providers have a solution to the problem of limited or no bank support resulting from federal regulations still on the books. Also, this system provides businesses with an advanced client management system. A majority of point-of-sale systems can be set up with the company’s gateway, and it lessens the need to deal in cash. This cuts down on security concerns for the legal cannabis industry.

The Sacramento Bee reported in October 2017 that legalized cannabis is still a cash business, and dangerous (http://ibn.fm/LRMrM). This is an issue that Medical Cannabis Payment Solutions is aggressively addressing. It is bringing to the marketplace the first and only comprehensive card processing operation of its type. The company’s system will process approximately 60 million transactions (http://ibn.fm/x2Nnw). The system will securely, safely and in a totally transparent manner issue one million new cards.

Nonetheless, the “Go” system still facilitates cash transactions for medical and recreational cannabis businesses. A business can accept cash with an understanding that it has a safe and user-friendly way in which to manage cash with deposits, withdrawals, spending and transfers all out of one seamless system. At its heart, the system is a link between a bank and a dispensary. The payment solution card enables patients and customers to link checking accounts from any United States bank to their “Go” accounts. The benefit to customers is speed and convenience in purchasing state-licensed products, which they can do directly from their bank accounts (http://ibn.fm/ZIFEk).

Offering the benefits of banking and merchant processing, Medical Cannabis Payment Solutions continues to innovate in the legal cannabis sector. The company’s goal is to help businesses operate legally and process payments securely. Regulatory compliant and dedicated to this mission, Medical Cannabis Payment Solutions offers its customers and stakeholders new ways to do business in a burgeoning industry.

For more information, visit the company’s website at www.PayWithGo.com